Jaguar Health, Inc. (NASDAQ:JAGX – Get Rating) was the target of a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 6,250,000 shares, an increase of 15.3% from the August 15th total of 5,420,000 shares. Currently, 11.6% of the company’s shares are short sold. Based on an average daily trading volume, of 4,330,000 shares, the days-to-cover ratio is currently 1.4 days.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in JAGX. Millennium Management LLC raised its stake in Jaguar Health by 152.3% during the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 321,795 shares during the last quarter. Virtu Financial LLC raised its stake in Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 99,073 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Jaguar Health by 153.3% during the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 33,148 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Jaguar Health during the first quarter valued at $1,079,000. Finally, Citigroup Inc. purchased a new position in Jaguar Health during the first quarter valued at $34,000. Hedge funds and other institutional investors own 7.40% of the company’s stock.
Analyst Ratings Changes
Separately, StockNews.com started coverage on Jaguar Health in a research note on Saturday. They issued a “hold” rating for the company.
Jaguar Health Trading Down 13.6 %
Jaguar Health (NASDAQ:JAGX – Get Rating) last released its earnings results on Monday, August 22nd. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. The company had revenue of $2.92 million during the quarter. Jaguar Health had a negative return on equity of 486.62% and a negative net margin of 652.35%. Equities research analysts predict that Jaguar Health will post -0.67 earnings per share for the current fiscal year.
Jaguar Health Company Profile
Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Get a free copy of the StockNews.com research report on Jaguar Health (JAGX)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.